Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Sensitive Primary Peritoneal Carcinoma”

75 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 75 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Study completedNCT00230542
What this trial is testing

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Dana-Farber Cancer Institute 44
Testing effectiveness (Phase 2)Ended earlyNCT03891576
What this trial is testing

Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Mario Negri Institute for Pharmacological Research 83
Testing effectiveness (Phase 2)Looking for participantsNCT07024784
What this trial is testing

Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Who this might be right for
Gynecologic CancersPlatinum-Sensitive Ovarian CancerFallopian Tube Cancer+1 more
AbbVie 377
Not applicableApproved For MarketingNCT03079687
What this trial is testing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Who this might be right for
Ovarian Cancer
AstraZeneca
Early research (Phase 1)Study completedNCT01314105
What this trial is testing

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal Neoplasms
Boehringer Ingelheim 19
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Large-scale testing (Phase 3)UnknownNCT00532194
What this trial is testing

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Medical Research Council 486
Testing effectiveness (Phase 2)Study completedNCT03759587
What this trial is testing

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 19
Testing effectiveness (Phase 2)Study completedNCT00020696
What this trial is testing

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Large-scale testing (Phase 3)Active Not RecruitingNCT00565851
What this trial is testing

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Clear Cell AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+22 more
National Cancer Institute (NCI) 1,052
Testing effectiveness (Phase 2)WithdrawnNCT00369954
What this trial is testing

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Who this might be right for
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Study completedNCT00217568
What this trial is testing

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Who this might be right for
Ovarian CancerPeritoneal Cavity Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT02983799
What this trial is testing

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 272
Early research (Phase 1)Study completedNCT01281514
What this trial is testing

Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Who this might be right for
Fallopian Tube CancerPeritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT05456685
What this trial is testing

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
High Grade Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
AbbVie 125
Testing effectiveness (Phase 2)Study completedNCT01188876
What this trial is testing

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Massachusetts General Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT00582205
What this trial is testing

Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma+1 more
University of Oklahoma 21
Testing effectiveness (Phase 2)Looking for participantsNCT05231122
What this trial is testing

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Who this might be right for
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more
Roswell Park Cancer Institute 80
Load More Results